Beijing Scitech-MQ Pharmaceuticals Ltd. described receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors reported to be useful for the treatment of cancer.
China Pharmaceutical University and Shanghai Institute of Materia Medica of the Chinese Academy of Sciences have patented benzimidazole compounds acting as ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) inhibitors reported to be useful for the treatment of cancer, infections, autoimmune disease and inflammatory disorders.
Researchers from Interius Biotherapeutics Inc. presented the development and preclinical evaluation of a novel gene therapy candidate, INT-2104, as potential candidate for the treatment of B-cell malignancies.
“From such a stick, such a splinter,” is a popular Spanish saying to explain how a son resembles his father. Like father, like son. The first Spotlight on Immuno-Oncology conference of the American Society of Gene & Cell Therapy (ASGCT) is the splinter of the ASGCT annual meeting, which brought together a group of experts in this field. It took place on Aug. 1 and 2, 2023, starting with a series of talks on “B Cell Malignancies and Beyond.”
Precision medicine startup Solu Therapeutics has raised $31 million in an oversubscribed seed round to advance a therapeutic candidate based on technology that identifies cell surface, tumor-associated targets that antibodies alone fail to latch onto. The company was founded by venture capital firm Longwood Fund and has high hopes for its cytotoxicity targeting chimera platform. “[It] has the potential to unlock new tumor-associated antigens and develop molecules that deplete pathogenic immune cells and extend the half-life of small-molecule antagonists and agonists,” CEO and co-founder of Solu, David Donabedian, told BioWorld.
Research at Genfleet Therapeutics Inc. has led to the development of mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer.
Mitogen-activated protein kinase kinase (MAP2K; MEK; MAPKK) inhibitors have been reported in an Immuneering Corp. patent as potentially useful for the treatment of cancer.
Recludix Pharma Inc. has disclosed signal transducer and activator of transcription 3 (STAT3) and/or STAT6 inhibitors reported to be useful for the treatment of cancer and inflammatory disorders.
The FDA has cleared Qualigen Therapeutics Inc.’s IND application for QN-302, a potential best-in-class small molecule G-Quadruplex (G4)-selective transcription inhibitor.
RSS
